Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

Resolvin D1 in Psoriasis Before and After Narrowband UVB Phototherapy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03483311
Recruitment Status : Recruiting
First Posted : March 30, 2018
Last Update Posted : March 30, 2018
Sponsor:
Information provided by (Responsible Party):
Maha Fathy Elmasry, Cairo University

Brief Summary:
• Assessment of tissue level of resolvin D1 in psoriasis in comparison to its level in healthy controls in order to verify its role in the pathogenesis of psoriasis.

Condition or disease Intervention/treatment Phase
Psoriasis Other: skin biopsy before and after NB-UVB phototherapy Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Estimation of Tissue Level of Resolvin D1 in Psoriasis Before and After Narrowband UVB Phototherapy: a Case-control Study.
Actual Study Start Date : March 1, 2018
Estimated Primary Completion Date : September 2018
Estimated Study Completion Date : September 2018

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis

Arm Intervention/treatment
Experimental: psoriasis patients
Tissue levels of resolvin D1 in psoriatic patients before and after NB-UVB.
Other: skin biopsy before and after NB-UVB phototherapy
skin biopsy before and after NB-UVB phototherapy to measure tissue resolvin D1

Experimental: controls
Tissue levels of resolvin D1 in controls
Other: skin biopsy before and after NB-UVB phototherapy
skin biopsy before and after NB-UVB phototherapy to measure tissue resolvin D1




Primary Outcome Measures :
  1. Tissue levels of resolvin D1 in psoriatic patients before and after NB-UVB. [ Time Frame: 6 months ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Patients with psoriasis (adults and children above 12years)
  • Both sexes.
  • New cases or cases not receiving any treatment for at least 3 months ago.

Exclusion Criteria:

  • Any contraindication to phototherapy treatment (e.g. Photosensitizing creams or medications, past skin cancer, especially melanoma, etc...)
  • Erythrodermic and pustular psoriasis.
  • History of autoimmune diseases or other systemic diseases (e.g. Alzheimer's disease, fibromyalgia, cystic fibrosis)

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03483311


Contacts
Layout table for location contacts
Contact: Maha Fathy Elmasry, MD 01222633740 mahafathy1214@gmail.com

Locations
Layout table for location information
Egypt
Maha Fathy Elmasry Recruiting
Cairo, Egypt, 11562
Contact: Maha Fathy Elmasry, MD    01222633740    mahafathy1214@gmail.com   
Sponsors and Collaborators
Cairo University
Investigators
Layout table for investigator information
Principal Investigator: Maha Elmasry Cairo University

Layout table for additonal information
Responsible Party: Maha Fathy Elmasry, principal investigator, Cairo University
ClinicalTrials.gov Identifier: NCT03483311     History of Changes
Other Study ID Numbers: Dermatology7
First Posted: March 30, 2018    Key Record Dates
Last Update Posted: March 30, 2018
Last Verified: March 2018

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Layout table for MeSH terms
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases